AU2002357191A1 - Derivatives of isoindigo, indigo and indirubin and use in treating cancer - Google Patents
Derivatives of isoindigo, indigo and indirubin and use in treating cancerInfo
- Publication number
- AU2002357191A1 AU2002357191A1 AU2002357191A AU2002357191A AU2002357191A1 AU 2002357191 A1 AU2002357191 A1 AU 2002357191A1 AU 2002357191 A AU2002357191 A AU 2002357191A AU 2002357191 A AU2002357191 A AU 2002357191A AU 2002357191 A1 AU2002357191 A1 AU 2002357191A1
- Authority
- AU
- Australia
- Prior art keywords
- derivatives
- isoindigo
- compound
- indigo
- indirubin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- MLCPSWPIYHDOKG-BUHFOSPRSA-N (3e)-3-(2-oxo-1h-indol-3-ylidene)-1h-indol-2-one Chemical class O=C\1NC2=CC=CC=C2C/1=C1/C2=CC=CC=C2NC1=O MLCPSWPIYHDOKG-BUHFOSPRSA-N 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 235000000177 Indigofera tinctoria Nutrition 0.000 title abstract 2
- 229940097275 indigo Drugs 0.000 title abstract 2
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 title abstract 2
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 title 1
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/021,589 US6566341B1 (en) | 2001-12-13 | 2001-12-13 | Derivative of isoindigo, indigo and indirubin for the treatment of cancer |
| US10/021,589 | 2001-12-13 | ||
| US40726702P | 2002-09-03 | 2002-09-03 | |
| US60/407,267 | 2002-09-03 | ||
| PCT/US2002/039866 WO2003051900A1 (en) | 2001-12-13 | 2002-12-13 | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002357191A1 true AU2002357191A1 (en) | 2003-06-30 |
Family
ID=26694875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002357191A Abandoned AU2002357191A1 (en) | 2001-12-13 | 2002-12-13 | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6933315B2 (https=) |
| EP (1) | EP1458734B1 (https=) |
| JP (1) | JP2005516938A (https=) |
| AT (1) | ATE484514T1 (https=) |
| AU (1) | AU2002357191A1 (https=) |
| CA (1) | CA2469649C (https=) |
| DE (1) | DE60237993D1 (https=) |
| WO (1) | WO2003051900A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563525B2 (en) | 2004-01-12 | 2013-10-22 | Natrogen Therapeutics International, Inc. | Methods of treating an inflammatory-related disease |
| US7582670B2 (en) | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
| US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| US20100098702A1 (en) * | 2008-09-16 | 2010-04-22 | Longgui Wang | Method of treating androgen independent prostate cancer |
| US8748475B2 (en) | 2004-01-12 | 2014-06-10 | Natrogen Therapeutics International, Inc. | Methods and compositions for treating lupus |
| CN101074229B (zh) * | 2007-06-08 | 2010-09-01 | 无锡杰西医药科技有限公司 | 7-氮杂靛玉红和7-氮杂异靛蓝衍生物制备及其药学用途 |
| CN101426268B (zh) * | 2007-11-02 | 2010-08-25 | 大唐移动通信设备有限公司 | 导频资源分配方法、系统和设备 |
| US8563595B2 (en) * | 2008-11-14 | 2013-10-22 | Board Of Regents, The University Of Texas System | Treatment of cancer with complex organic-inorganic pigment compositions |
| US20150087687A1 (en) * | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| CN110123763A (zh) * | 2012-06-21 | 2019-08-16 | 法斯瑞斯公司 | 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法 |
| CN103333161B (zh) * | 2013-05-28 | 2015-09-30 | 滁州市洛达生物科技有限公司 | 1’-氧代靛玉红的制备和用途 |
| CN110740991B (zh) | 2017-05-26 | 2023-07-04 | 大鹏药品工业株式会社 | 新型联苯化合物或其盐 |
| JP6738962B2 (ja) * | 2017-05-26 | 2020-08-12 | 大鵬薬品工業株式会社 | 新規なビフェニル化合物を用いた抗腫瘍効果増強剤 |
| US12435128B2 (en) | 2017-05-31 | 2025-10-07 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| WO2020117487A1 (en) * | 2018-12-07 | 2020-06-11 | Natrogen Therapeutics International, Inc. | Polymorphic form of meisoindigo and modified formulation of meisoindigo |
| MX2022005812A (es) | 2019-11-13 | 2022-08-16 | Taiho Pharmaceutical Co Ltd | Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina. |
| US11345818B1 (en) | 2020-12-29 | 2022-05-31 | Industrial Technology Research Institute | Dye for fiber and dyeing method |
| WO2022232243A1 (en) * | 2021-04-27 | 2022-11-03 | Curapep Llc | Compositions for wound relief and inhibiting a phd protein and methods of treatment |
| CN114920728B (zh) * | 2022-05-27 | 2023-10-20 | 中南大学 | 一种甲异靛衍生物及其制备方法与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS617254A (ja) * | 1984-06-20 | 1986-01-13 | Isukura Sangyo Kk | ビスインドリノンおよびそれを主成分とする制癌剤 |
| US5696092A (en) * | 1995-03-07 | 1997-12-09 | George Washington University | Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers |
| JP2002516851A (ja) * | 1998-05-29 | 2002-06-11 | ゲルハルト アイゼンブランド | サイクリン依存性キナーゼを阻害する医薬製造のためのインジゴイドビスインドール誘導体の使用 |
| HRP20010735A2 (en) * | 1999-04-12 | 2002-12-31 | Gerhard Eisenbrand | Indigoid bisindole derivatives |
| EP1218004B1 (en) * | 1999-04-12 | 2009-04-08 | Heinz Herbert Fiebig | 5-methyl indirubin for use in the treatment of human solid tumors |
-
2002
- 2002-12-13 CA CA2469649A patent/CA2469649C/en not_active Expired - Lifetime
- 2002-12-13 WO PCT/US2002/039866 patent/WO2003051900A1/en not_active Ceased
- 2002-12-13 DE DE60237993T patent/DE60237993D1/de not_active Expired - Lifetime
- 2002-12-13 AU AU2002357191A patent/AU2002357191A1/en not_active Abandoned
- 2002-12-13 EP EP02805123A patent/EP1458734B1/en not_active Expired - Lifetime
- 2002-12-13 AT AT02805123T patent/ATE484514T1/de not_active IP Right Cessation
- 2002-12-13 JP JP2003552781A patent/JP2005516938A/ja active Pending
-
2004
- 2004-06-10 US US10/864,458 patent/US6933315B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1458734B1 (en) | 2010-10-13 |
| CA2469649A1 (en) | 2003-06-26 |
| JP2005516938A (ja) | 2005-06-09 |
| CA2469649C (en) | 2011-05-03 |
| DE60237993D1 (de) | 2010-11-25 |
| US20040225002A1 (en) | 2004-11-11 |
| WO2003051900A1 (en) | 2003-06-26 |
| ATE484514T1 (de) | 2010-10-15 |
| EP1458734A1 (en) | 2004-09-22 |
| US6933315B2 (en) | 2005-08-23 |
| EP1458734A4 (en) | 2007-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002357191A1 (en) | Derivatives of isoindigo, indigo and indirubin and use in treating cancer | |
| MXPA05006940A (es) | Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide. | |
| NO992524L (no) | Konsenserte bicykliske pyrimidin-derivater | |
| EP1024145A3 (en) | Novel azalides and methods of making same | |
| EP2105135A3 (en) | Pharmaceutical compositions for treating cancer | |
| PL367682A1 (en) | Dolastatin 10 derivatives | |
| MXPA04005156A (es) | Antagonistas del receptor de adenosina a2a. | |
| GB0112348D0 (en) | Compounds | |
| CA2464758A1 (en) | Combination therapy comprising zd6474 and a taxane | |
| PL342614A1 (en) | Anticarcinogenic drugs | |
| WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | |
| IL150817A0 (en) | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | |
| IL136733A0 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| EP4591940A3 (en) | Deoxy- cytidine derivatives for use in cancer therapies | |
| EP0281070A3 (en) | Pharmaceutical composition for the treatment of cancer | |
| BG106180A (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| RU2005131723A (ru) | Лечение пролиферативных заболеваний производными эпотилона и излучением | |
| WO2003080624A3 (en) | Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases | |
| WO2001007029A3 (en) | Substituted guanidines and the use thereof | |
| WO2005035500A3 (en) | Therapeutic agents useful for treating pain | |
| TW200730177A (en) | 4 anilino-3-quinolinecarbonitriles for the treatment of cancer | |
| ATE346080T1 (de) | Steroid-verbindungen mit anti-tumoraler wirkung | |
| MX2026000917A (es) | Radiofarmacos dirigidos a psma para el tratamiento del cancer | |
| AU2003267751A1 (en) | Use of epothilone derivatives for the treatment of hyperparathyroidism | |
| WO2024073328A3 (en) | Vanoxerine for use in the treatment of brain cancer, breast cancer, pancreatic cancer and lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |